Perlecan Domain-V Enhances Neurogenic Brain Repair After Stroke in Mice

Authors:

Abstract
The extracellular matrix fragment perlecan domain V is neuroprotective and functionally restorative following experimental stroke. As neurogenesis is an important component of chronic post-stroke repair, and previous studies have implicated perlecan in developmental neurogenesis, we hypothesized that domain V could have a broad therapeutic window by enhancing neurogenesis after stroke. We demonstrated that domain V is chronically increased in the brains of human stroke patients, suggesting that it is present during post-stroke neurogenic periods. Furthermore, perlecan deficient mice had significantly less neuroblast precursor cells after experimental stroke. Seven-day delayed domain V administration enhanced neurogenesis and restored peri-infarct excitatory synaptic drive to neocortical layer 2/3 pyramidal neurons after experimental stroke. Domain V’s effects were inhibited by blockade of α2β1 integrin, suggesting the importance of α2β1 integrin to neurogenesis and domain V neurogenic effects. Our results demonstrate that perlecan plays a previously unrecognized role in post-stroke neurogenesis and that delayed DV administration after experimental stroke enhances neurogenesis and improves recovery in an α2β1 integrin-mediated fashion. We conclude that domain V is a clinically relevant neuroprotective and neuroreparative novel stroke therapy with a broad therapeutic window.
Funding Information
  • National Institutes of Health (R21 NS079960, R21 NS088608, R01 NS092552)
  • American Heart Association (Predoctoral)
  • Sir Charles Hercus Fellowship from the Health Research Council of New Zealand (NA)
  • Health Research Council of New Zealand (NA)
  • Royal Society of New Zealand Marsden Fund (NA)
  • Neurological Foundation of New Zealand (NA)

This publication has 48 references indexed in Scilit: